Publications by authors named "K Jeannot"
Background: Meropenem-vaborbactam (MEM-VAB) is a novel carbapenem-beta-lactamase-inhibitor combination that demonstrates activity against carbapenem-resistant (CR) Gram-negative bacteria, and more specifically KPC-producers, since vaborbactam is an effective inhibitor of KPC enzymes in vitro. This study aimed to describe the initial uses and efficacy of MEM-VAB for compassionate treatment during the first 21 months following its early access in France.
Method: A national multicenter retrospective study was conducted, including all patients who received at least one dose of MEM-VAB between 20 July 2020, and 5 April 2022.
Cefiderocol susceptibility testing: the challenge of disc diffusion.
Clin Microbiol Infect
January 2025
Evolution of the highly successful and multidrug resistant clone ST111 in Pseudomonas aeruginosa involves serotype switching from O-antigen O4 to O12. How expression of a different O-antigen serotype alters pathogen physiology to enable global dissemination of this high-risk clone-type is not understood. Here, we engineered isogenic laboratory and clinical P.
View Article and Find Full Text PDFArticle Synopsis
- Cefepime-enmetazobactam is a new antibiotic combination that effectively targets multidrug-resistant Enterobacterales, including ESBL producers, and was tested against various resistant bacteria.
- The study evaluated the minimum inhibitory concentration (MIC) of cefepime-enmetazobactam compared to other antibiotic combinations on over 2,200 strains of carbapenem-resistant Enterobacterales and other pathogens.
- Results showed that while cefepime-enmetazobactam had good activity against OXA-48 producers, it offered no significant advantage over cefepime alone in treating Pseudomonas aeruginosa and Acinetobacter baumannii, highlighting the need for further in vivo testing.
Background: Cefiderocol is a siderophore-conjugated cephalosporin increasingly used in the management of Achromobacter infections. Testing for cefiderocol susceptibility is challenging with distinct recommendations depending on the pathogens.
Objectives: We evaluated the performance of commercial tests for testing cefiderocol susceptibility in the Achromobacter genus and reviewed the literature.